187 related articles for article (PubMed ID: 36142814)
1. Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional Validation.
Vishnubalaji R; Abdel-Razeq H; Gehani S; Albagha OME; Alajez NM
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142814
[TBL] [Abstract][Full Text] [Related]
2. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
4. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Zheng T; Pang Z; Zhao Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
[TBL] [Abstract][Full Text] [Related]
5. Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial.
Freitas AJA; Nunes CR; Mano MS; Causin RL; Santana IVV; de Oliveira MA; Calfa S; Silveira HCS; de Pádua Souza C; Marques MMC
Sci Rep; 2023 Dec; 13(1):21411. PubMed ID: 38049525
[TBL] [Abstract][Full Text] [Related]
6. A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence.
Fournier MV; Goodwin EC; Chen J; Obenauer JC; Tannenbaum SH; Brufsky AM
Sci Rep; 2019 Oct; 9(1):14863. PubMed ID: 31619719
[TBL] [Abstract][Full Text] [Related]
7. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
Pérez-Pena J; Tibor Fekete J; Páez R; Baliu-Piqué M; García-Saenz JÁ; García-Barberán V; Manzano A; Pérez-Segura P; Esparis-Ogando A; Pandiella A; Gyorffy B; Ocana A
Front Immunol; 2019; 10():2802. PubMed ID: 31921107
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
Zhang L; Wang XI; Zhang S
Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
[TBL] [Abstract][Full Text] [Related]
9. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
Xu X; Zhao W; Liu C; Gao Y; Chen D; Wu M; Li C; Wang X; Song X; Yu J; Liu Z; Yu Z
BMC Cancer; 2024 Jan; 24(1):13. PubMed ID: 38166846
[TBL] [Abstract][Full Text] [Related]
10. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
Yu KD; Zhu R; Zhan M; Rodriguez AA; Yang W; Wong S; Makris A; Lehmann BD; Chen X; Mayer I; Pietenpol JA; Shao ZM; Symmans WF; Chang JC
Clin Cancer Res; 2013 May; 19(10):2723-33. PubMed ID: 23549873
[TBL] [Abstract][Full Text] [Related]
11. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
[TBL] [Abstract][Full Text] [Related]
12. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
13. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
14. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Sharma P; López-Tarruella S; García-Saenz JA; Khan QJ; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Monte-Millán MD; González-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortés J; Fuentes-Rivera H; Morales DB; Márquez-Rodas I; Perou CM; Lehn C; Wang YY; Klemp JR; Mammen JV; Wagner JL; Amin AL; O'Dea AP; Heldstab J; Jensen RA; Kimler BF; Godwin AK; Martín M
Clin Cancer Res; 2018 Dec; 24(23):5820-5829. PubMed ID: 30061361
[TBL] [Abstract][Full Text] [Related]
15. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Yin Y; Zhang P; Xu BH; Zhang BL; Li Q; Yuan P; Cai RG; Wang JY; Wang X; Xu XZ
J Huazhong Univ Sci Technolog Med Sci; 2013 Apr; 33(2):262-265. PubMed ID: 23592141
[TBL] [Abstract][Full Text] [Related]
16. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
[TBL] [Abstract][Full Text] [Related]
17. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
[TBL] [Abstract][Full Text] [Related]
18. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
19. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
